Delivery Order SPE2DB20D7059-SPE2DB25FQLY8
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $10,627.40 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 18, 2025, with completion scheduled for August 19, 2025. This firm fixed-price, competitively awarded contract with no set-aside designation leverages AmerisourceBergen's position as a major pharmaceutical distributor supporting federal medical procurement. The work will be performed at the company's corporate office in...
- The Defense Logistics Agency awarded a delivery order valued at $33,016.79 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This firm fixed-price contract represents a non-compete award and is performed at the awardee's location in Conshohocken, Pennsylvania. As a child order under a larger contract vehicle, this delivery order leverages AmerisourceBergen's established relationship with the...
- The Defense Logistics Agency awarded a delivery order valued at $5,533.31 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a firm fixed price structure. The award was made on August 5, 2025, with an ultimate completion date of August 6, 2025, and represents a non-set-aside competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will perform this delivery order from its corporate office location. This delivery order is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $35,020.92 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. This firm fixed-price delivery order, executed on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is...
- The Defense Logistics Agency awarded a delivery order valued at $5,763.31 to AmerisourceBergen Drug Corp for the supply of BIKTARVY (bictegravir/tenofovir alafenamide/emtricitabine) 50-200-25 mg tablets in a 30-count unit dosage. This non-competitive delivery order, issued on August 5, 2025, represents firm fixed-price pharmaceutical procurement to support federal medical supply requirements. The place of performance is AmerisourceBergen's facility in Conshohocken, Pennsylvania, with an ultimate...
- The Defense Logistics Agency awarded a delivery order valued at $4,437.80 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count unit of use packages). This firm fixed-price delivery order, issued on July 21, 2025, represents a competitively awarded contract with an ultimate completion date of July 22, 2025, and carries no set-aside designation. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $78,728.98 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price contract was executed on July 30, 2025, with an ultimate completion date of July 31, 2025. The contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child...
- The Defense Logistics Agency awarded a delivery order valued at $73,229.67 to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) on August 13, 2025, with completion targeted for August 14, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded contract fulfilling federal pharmaceutical procurement requirements. The award was placed to AmerisourceBergen's Corporate Office located in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order totaling $40,340.72 to AmerisourceBergen Drug Corp for the supply of BIKTARVY 50-200-25 mg tablets (30-count units). This competitively awarded, firm fixed-price delivery order was issued on July 18, 2025, with an ultimate completion date of July 21, 2025, and represents a non-set-aside procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor and healthcare solutions provider...
- The Defense Logistics Agency awarded a $4,118.45 firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of BIKTARVY 50-200-25 mg tablets in quantities of 30 units. The delivery was completed by July 23, 2025, and performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This was a competitively awarded contract with no set-aside designation, reflecting the agency's standard procurement practices for pharmaceutical supplies...
- SPE2DB20D7059Indefinite Delivery Contract
- SPE2DB20D7059-SPE2DB25FQLY8Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for BIKTARVY 50-200-25 mg tablets (30-count units) with a ceiling value of $1,548.15. This is a firm fixed price delivery order issued on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract utilizes no set-aside designation and represents a competitive award to the vendor's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a prime vendor for the Defense Logistics Agency's Medical Supply Chain, AmerisourceBergen Drug Corp serves as a critical pharmaceutical distributor supporting military healthcare systems and the Defense Health Agency. The contract vehicle enables the company to supply a comprehensive range of pharmaceutical products, including brand-name and generic medications, across multiple therapeutic domains to support federal medical procurement needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 7/23/25 |